Advertisement

Topics

EHA 2019: Imetelstat in lower risk myelodysplastic syndromes refractory to erythropoietic stimulating agents

03:30 EDT 14 Jun 2019 | ecancermedicalscience

Lower risk MDS are characterised by a relatively low risk of progression to acute myeloid leukaemia (AML), but by chronic and debilitating anaemia, that responds inconstantly and transiently to ESAs (including EPO and darpbepoietin), requiring after ESA...

Original Article: EHA 2019: Imetelstat in lower risk myelodysplastic syndromes refractory to erythropoietic stimulating agents

NEXT ARTICLE

More From BioPortfolio on "EHA 2019: Imetelstat in lower risk myelodysplastic syndromes refractory to erythropoietic stimulating agents"

Advertisement
Quick Search
Advertisement
Advertisement